Michael Zdenek David, MS, MD, PhD
Assistant Professor of Medicine and Epidemiology
Dr. David, an infectious diseases physician, is the director of the MRSA [methicillin-resistant S. aureus] Research Program and also the director of the Skin and Soft Tissue Clinic at Penn. Before moving to Penn in 2017, for eight years he was on the faculty of the Department of Medicine of the University of Chicago. He works on the inpatient consultation service and in the outpatient clinic, providing care for patients with a variety of infections.
He has focused his research for more than a decade on the epidemiology of Staphylococcus aureus infections. With the emergence of community-associated MRSA strains in the late 1990s, the epidemiology of MRSA infections in the United States completely changed. Whereas in the 1990s MRSA infections were exclusively found in the health care setting, by 2005, the majority of MRSA infections had their onset outside of health care facilities. Dr. David has written extensively on the molecular and clinical epidemiology of MRSA infections in these “new” sites, such as jails and households, as well as in medical settings. He has undertaken studies with collaborators on the epidemiology of MRSA infections and asymptomatic colonization in the United States generally, in rural Southwestern Alaska, in households, in the Dallas County Jail in Texas and the Cook County Jail in Chicago, among HIV-infected patients, and in emergency departments. Current interests include the evolutionary adaptation of S. aureus to sites of infection in blood, skin, and bone; the distinct characteristics of healthcare-associated S. aureus strains; and the spread of S. aureus within healthcare facilities.
Dr. David is now working on several projects in antimicrobial stewardship, infection control, and SARS-Cov-2 epidemiology with Dr. Ebbing Lautenbach and other colleagues as part of the CDC Prevention EpiCenters Program site at the University of Pennsylvania.
In long-term current research projects, previously funded by a K23 award and now by an R01 award from NIAID, Dr. David is examining host, environmental and microbial risk factors for recurrent S. aureus infections. Using data from whole-genome sequencing of bacterial genomes, he is examining the intra-host evolution of S. aureus during recurrent infections and asymptomatic colonization in patients at high risk of infections. The overarching goal of these studies is to define the impact on colonizing S. aureus isolates of antibiotic exposures and also the evolutionary trajectory of S. aureus on the human body that predicts persistence of colonization, clinically significant infections, and loss of colonization. With this information, physicians may be able to define high-risk patients who would benefit from interventions to prevent S. aureus infections.
Dr. David has co-edited a volume of 47 clinical cases in infectious diseases to provide a guide to developing differential diagnoses in the field (Springer, 2018). He is generally interested in the history of infectious diseases, particularly tuberculosis, as well as the history of Russian medicine and health.
Content Area Specialties
Bacterial antimicrobial resistance, health care infection control, Staphylococcus aureus, MRSA, influenza, SARS-CoV-2
Cohort studies, molecular epidemiology of infectious diseases, Randomized, controlled trials